The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups
Open accessAbstract
Schizophrenia is characterized by physical (mainly metabolic and cardiovascular) comorbidity and shortened lifespan. High sensitivity C-reactive protein (hs-CRP), an inflammatory marker of hepatic origin linked to metabolic and cardiovascular diseases and mortality in the general population, has been reported to be elevated in people with schizophrenia. However, the relationship of hs-CRP to psychiatric and medical risk factors, after controlling for potentially confounding variables such as smoking, is not well established in schizophrenia. We assessed hs-CRP levels along with various demographic, psychiatric, and metabolic measures in 88 clinically stable outpatients with schizophrenia or schizoaffective disorder and 71 age epoch-matched comparison subjects with no history of a major psychiatric illness. hs-CRP levels were significantly higher in individuals with schizophrenia than in comparison subjects. Higher hs-CRP levels in the schizophrenia group were associated with female gender, more severe negative symptoms, greater medical comorbidity, and worse metabolic risk factors including BMI, fasting glucose, and hemoglobin A1c levels. hs-CRP was not related to age, race, education, smoking status, antipsychotic dosage, or cognitive impairment. Longitudinal studies are needed to investigate the relationship between hs-CRP and long-term health outcomes including metabolic syndrome, cardiovascular disease, and mortality in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and used in clinical practice mainly as a biomarker of infection, chronic disease state, and chronic low-grade inflammation [30,32].”
From C-Reactive protein as a biomarker for major depressive disorder? (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,710
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
Scale for the Assessment of Negative Symptoms
Andreasen, N. C. (1982) · PsycTESTS Dataset · doi:10.1037/t12696-000 · Cited by 1,888
Black, S., Kushner, I., & Samols, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400025200 · Cited by 1,844
Shunk, A. W., Davis, A. S., & Dean, R. S. (2006) · Applied Neuropsychology · doi:10.1207/s15324826an1304_9 · Cited by 1,540
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–109 of 109
A novel ROMK mutation in a child presenting with Bartter Syndrome Type 2
Malik, M. A., Conwell, L. S., Bichet, D. G., Sochett, E. B., & Hebert, D. (2007) · Pediatric Nephrology
CRP and its relation to cognitive performance in schizophrenia patients: a cross-sectional study
Khalaf, O. O., Kamal, S., El-Samahy, S. A.-M., & Abdelfattah, W. (2022) · Egyptian Journal of Psychiatry · doi:10.4103/ejpsy.ejpsy_44_21
Sun, X., Xu, Y., Wu, Y., Li, M., Qiu, Y., Su, Q., Wang, J., Li, J., & Mao, F. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.02.002
Pachi, A., Tselebis, A., Kavourgia, E., Soultanis, N., Kasimis, D., Sikaras, C., Baras, S., & Ilias, Ι. (2025) · Healthcare · doi:10.3390/healthcare13141754
Wang, T., Wang, L., Zhao, P., Sun, J.-J., Gao, L.-N., Li, J., & Zhao, Y.-Q. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.v16.i2.112575
Zhao, C., Cath, D. C., van Dalfsen, J. H., Milaneschi, Y., Naderi, E., Penninx, B. W. J. H., Bruggeman, R., Schoevers, R. A., & Alizadeh, B. Z. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106999
Metadata
- Authors
- Joseph, J., Depp, C., Martin, A. S., Daly, R. E., Glorioso, D. K., Palmer, B. W., & Jeste, D. V.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Jeste, Dilip V.
- ORCID
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 168
- Issue
- 1-2
- Pages
- 456-460
- ISSN
- 0920-9964 (ISSN-L)
- PMC
- PMC4591213
- OpenAlex
- W2142231500
- Cited by
- 109
- References
- 55
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 9 · 2022: 14 · 2021: 8 · 2020: 8 · 2019: 11 · 2018: 15 · 2017: 15 · 2016: 13
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Mental Health (MH019934, R01MH094151, T32MH019934)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- high-sensitivity C-reactive protein, schizophrenia
- MeSH terms
- Adult, Aged, C-Reactive Protein, Female, Humans, Longitudinal Studies, Male, Metabolic Diseases, Middle Aged, Outpatients, Psychotic Disorders, Risk Factors, Schizophrenia, Sex Characteristics, Biomarkers, Comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
